Targeted BEACOPP Variants in Patients With Newly Diagnosed Advanced Classical Hodgkin Lymphoma

University of Cologne100 enrolled

Overview

The Purpose of this trial is: * to determine complete response rate (CRR) after six cycles of chemotherapy * to determine complete remission rate (CR/CRr) as final treatment outcome after completion of treatment

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Hodgkin Lymphoma

Interventions

EtoposideDRUG

CyclophosphamideDRUG

DoxorubicinDRUG

PrednisoneDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically proven classical Hodgkin lymphoma * First diagnosis, no previous treatment, age: 18-60 years * Stage IIB with large mediastinal mass and/or extranodal lesions, stage III or IV disease Exclusion Criteria: * Composite lymphoma or nodular lymphocyte- predominant Hodgkin lymphoma (NLPHL) * Previous malignancy * Prior chemotherapy or radiation

Locations (1)

1st Dept. of Medicine, Cologne University Hospital

Cologne, Germany

Outcomes

Primary Outcomes

Response rate (RR) after six cycles of chemotherapy

Time frame: 18 weeks

Complete remission rate (CR/CRr) as final treatment outcome after completion of treatment

Time frame: 18 weeks

Secondary Outcomes

Progression Free Survival (PFS)

Time frame: 2 years

Overall survival (OS)

Time frame: 2 years

Adverse event rate

Time frame: 2 years

Dose reduction rate

Time frame: 18 weeks

Relative dose intensity

Time frame: 18 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.